FAP mRNA vaccine study for advanced solid tumors
Part of Cancer clinical trials.
This study tests a new mRNA vaccine that targets a protein called FAP, which is found in many solid tumors. It is for people whose cancer has not responded to or cannot tolerate standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Diagnosed with an advanced solid tumor, such as lung, colorectal, or pancreatic cancer
- Standard treatments no longer work or cause too many side effects
- At least one tumor that can be measured on a scan
- Good enough health to be up and active (able to do light housework or office work)
- Expected to live at least 3 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This study uses a special imaging agent that targets a protein called FAP found on many solid tumors. It helps doctors see tumors more clearly and stage them better. If you have a confirmed solid tumor and are able to undergo PET or SPECT/CT scans, this trial may help improve how your cancer is evaluated.
This trial tests a new mRNA vaccine that targets a unique part of your tumor cells, given together with an immunotherapy drug (anti-PD-1). It is for people with advanced solid tumors that have not responded to standard treatments.
This study tests two new mRNA-based vaccines, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the vaccines are safe and can help shrink or control the cancer.
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.